GemPharmatech Co., Ltd.

Equities

688046

CNE100005964

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. 23:00:00 06/06/2024 BST 5-day change 1st Jan Change
11.61 CNY +1.75% Intraday chart for GemPharmatech Co., Ltd. -0.34% -42.38%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023. CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Correction: GemPharmatech Responds to US Legislation Concerns MT
GemPharmatech Responds to US Legislation Concerns MT
China's MGI Tech, GemPharmatech defend themselves after US bill proposed RE
Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023. CI
GemPharmatech Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares. CI
GemPharmatech Co., Ltd. authorizes a Buyback Plan. CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
GemPharmatech Appoints Board Chairman MT
GemPharmatech Co., Ltd.(XSSC:688046) added to S&P Global BMI Index CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
GemPharmatech Co., Ltd. Introduced NeoMab CI
GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GemPharmatech Co., Ltd.(SHSE:688046) added to Shanghai Stock Exchange Composite Index CI
GemPharmatech Co., Ltd.(SHSE:688046) added to Shanghai Stock Exchange A Share Index CI
GemPharmatech to Establish 20 Million Yuan Subsidiary; Shares Drop 3% MT
Gempharmatech Llc announced that it expects to receive $29 million in funding from GemPharmatech Co., Ltd. CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
GemPharmatech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
GemPharmatech announced that it has received $23.32 million in funding from CDH Investments, Sinopharm Group Co. Ltd. CI
Chart GemPharmatech Co., Ltd.
More charts
GemPharmatech Co Ltd, formerly Jiangsu Jicui Yaokang Biotechnology Co Ltd, is a China-based company principally engaged in the research, development, production and sales of experimental mouse models. The Company uses gene-editing and other technologies to produce mouse models. The Company also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.61 CNY
Average target price
21.13 CNY
Spread / Average Target
+82.03%
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW